Patents by Inventor Marc E. Rothenberg

Marc E. Rothenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9624545
    Abstract: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: April 18, 2017
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Marc E. Rothenberg, Thomas Xuefeng Lu
  • Publication number: 20170067111
    Abstract: A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.
    Type: Application
    Filed: November 1, 2016
    Publication date: March 9, 2017
    Inventors: Marc E. Rothenberg, Carrie Blanchard
  • Patent number: 9517238
    Abstract: The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: December 13, 2016
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mark Rochman, Marc E. Rothenberg
  • Publication number: 20160312282
    Abstract: The disclosure provides compositions and methods related to the diagnosis, prognosis, and treatment of inflammatory diseases and disorders, especially allergic inflammatory diseases and disorders.
    Type: Application
    Filed: April 12, 2016
    Publication date: October 27, 2016
    Inventors: Marc E. Rothenberg, Julie Caldwell
  • Publication number: 20160304960
    Abstract: The disclosure provides methods and compositions for diagnosing a patient eosinophilic esophagitis, the methods based upon the patient's gene expression profile for a panel of genes. The methods can also be used to exclude a diagnosis of chronic esophagitis.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventor: Marc E Rothenberg
  • Publication number: 20160177394
    Abstract: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.
    Type: Application
    Filed: January 6, 2016
    Publication date: June 23, 2016
    Inventors: Marc E. Rothenberg, Thomas Xuefeng Lu
  • Patent number: 9345763
    Abstract: Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 24, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Julie Caldwell
  • Publication number: 20160129012
    Abstract: The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Mark Rochman, Marc E. Rothenberg
  • Patent number: 9260756
    Abstract: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 16, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Thomas Xuefeng Lu
  • Publication number: 20150098952
    Abstract: CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 9, 2015
    Inventors: Francesca LEVI-SCHAFFER, Ido BACHELET, Ariel MUNITZ, Marc E. ROTHENBERG
  • Publication number: 20150045334
    Abstract: Embodiments of the invention are directed to methods of diagnosing eosinophilic esophagitis (EoE), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EoE, analyzing to obtain relatedness information relative to an EoE cohort and making a determination as to the EoE status of the subject, wherein an analysis indicating grouping with an EoE cohort or a quantitative score similar to that of an EoE cohort are indicative of EoE in the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EoE in a subject.
    Type: Application
    Filed: June 21, 2012
    Publication date: February 12, 2015
    Inventors: Marc E. Rothenberg, Ting Wen
  • Publication number: 20150038552
    Abstract: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventors: Marc E. Rothenberg, Thomas Xuefeng Lu
  • Publication number: 20140286896
    Abstract: Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.
    Type: Application
    Filed: June 25, 2012
    Publication date: September 25, 2014
    Applicant: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Julie Caldwell
  • Publication number: 20140228315
    Abstract: It has long been known that eosinopenia is observed during acute bacterial infection yet the mechanism remains undefined. Herein, we investigated the consequence of exposure to microbial products, specfically bacterial lipopolysaccharide (LPS), on eosinophil production. We demonstrate that developing murine eosinophils transiently express mRNA for six Toll-like receptors (TLR5) with highest expression of TLR2 and TLR4 throughout eosinophil development and nearly undetectable levels on mature eosinophils. LPS stimulation of eosinophil progenitors ex vivo markedly inhibited IL-5- mediated cellular proliferation and expansion Further LPS adrninistratwn in vivo reduced numbers of eosinophil progenitors in the bone marrow and blood in mice. Notably, LPS effectively reduced eosinophilia even in hypereosinophilic mice induced by the IL-S transgene.
    Type: Application
    Filed: June 18, 2012
    Publication date: August 14, 2014
    Inventors: Marc E. Rothenberg, Patricia C. Fulkerson
  • Publication number: 20130324435
    Abstract: Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor.
    Type: Application
    Filed: January 6, 2012
    Publication date: December 5, 2013
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Marc E. Rothenberg, Carine Blanchard
  • Patent number: 8409565
    Abstract: CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: April 2, 2013
    Inventors: Francesca Levi-Schaffer, Ido Bachelet, Ariel Munitz, Marc E. Rothenberg
  • Publication number: 20120283117
    Abstract: Eosinophilic esophagitis (EE), an emerging disorder with poorly understood pathogenesis, was examined. Esophageal tissue was analyzed by a genome wide microarray expression analysis. EE patients had a transcript signature involving 1% of the genome that was conserved across gender, age, and atopic status, and was distinct from that associated with chronic esophagitis (CE). The eosinophil specific chemokine eotaxin-3 was the top induced gene compared with normal controls. Levels C of eotaxin-3 mRNA and protein correlated with disease severity. A single nucleotide polymorphism in the human eotaxin-3 gene conferred susceptibility to disease. Mice deficient in the eotaxin-3 receptor (CCR-3) were protected from experimental EE. Eotaxin-3 was identified as a specific effector molecule, biomarker, and genetic risk factor for EE, and distinguished EE from CE.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 8, 2012
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventor: Marc E. ROTHENBERG
  • Publication number: 20110301046
    Abstract: The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products.
    Type: Application
    Filed: December 1, 2009
    Publication date: December 8, 2011
    Applicant: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Julie Caldwell
  • Patent number: 7879547
    Abstract: Several genes are upregulated in the lung of asthma or allergy sufferers. Many of the genes up-regulated in asthma are involved in arginine metabolism in the lung. Moreover, a set of 291 signature genes was found that can be used to indicate a patient's predilection for developing asthma or the patient's degree of suffering. Also, a set of 59 signature genes were found that indicate a patient's predilection for developing allergies. Many of the up-regulated genes relating to asthma were from the arginine metabolic pathway. Other genes, such as ADAM8, SPRR2A and SPRR2B were also strongly up-regulated in asthma. Treatment of asthma may be accomplished by administering compositions which decrease the levels of Arginase I, Arginase II, CAT2, or other arginase pathway members in the lung. Additionally, detection of altered levels of these proteins or the mRNA encoding them may be useful to diagnose the presence of asthma in a patient.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: February 1, 2011
    Assignee: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Nives Zimmermann
  • Publication number: 20090269774
    Abstract: A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.
    Type: Application
    Filed: June 26, 2009
    Publication date: October 29, 2009
    Applicant: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Marc E. Rothenberg, Carine Blanchard